documentation:oncology:meeting_notes_2017_oct-19
Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
|
documentation:oncology:meeting_notes_2017_oct-19 [2017/10/28 18:02] rimma_belenkaya created |
documentation:oncology:meeting_notes_2017_oct-19 [2017/10/30 15:17] (current) rimma_belenkaya |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}} | {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}} | ||
| + | |||
| + | **Next steps** | ||
| + | |||
| + | **I. Tasks to generate the minimal viable product** | ||
| + | |||
| + | 1. Diagnosis | ||
| + | |||
| + | a. Vocabulary Mapping | ||
| + | |||
| + | * Rely only on pre-coordination of SNOMED morphology and anatomy corresponding to ICD-O histology and topography. If a pre-coordinated SNOMED diagnosis does not exist, create OMOP-generated one. | ||
| + | * Present proposal for pre-coordinated terms to SNOMED. | ||
| + | |||
| + | |||
| + | b. Diagnosis identification and verification | ||
| + | |||
| + | * Sourced from cancer registry based on ICDO-O – >SNOMED mapping | ||
| + | * Sourced from EMR based on ICD-9/10 -> SNOMED mapping or ICDO-O – >ICD-9/10 -> SNOMED | ||
| + | * Compare the diagnoses and patient identified from the two sources | ||
| + | * Explore how ICD-9/10 diagnosis changes in EMR, if at all, through the course of the disease | ||
| + | |||
| + | c. Cancer diagnosis representation in OMOP CDM – possible extension to represent recurrences | ||
| + | |||
| + | 2. Staging | ||
| + | |||
| + | Choose vocabulary | ||
| + | ??? | ||
| + | |||
| + | 3. Treatments | ||
| + | |||
| + | a. Drugs | ||
| + | * Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary. | ||
| + | * Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations. | ||
| + | * Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available | ||
| + | * Work on cancer Drug Era algorithm and modeling in CDM | ||
| + | |||
| + | b. Overlay cancer registry treatment schema (first occurrence only) with EMR details to construct complete treatment regimen | ||
| + | |||
| + | c. Model representation of the treatment regimen (era) in the CDM | ||
| + | |||
| + | |||
| + | **II. Exploratory** | ||
| + | - Discuss with IMO procedure mappings to SNOMED and classification of cancer cases. | ||
| + | - Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens | ||
| + | - Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling | ||
| + | - Find a geneticist and oncologist to identify cancer-relevant genomic areas | ||
| + | - Find out if we can get cancer registry data from any of the “SEER” states | ||
| + | |||
| + | **III. Operational** | ||
| + | |||
| + | Document challenges related to extending OHDSI infrastructure to support cancer research for NCI | ||
| + | |||
| + | |||
documentation/oncology/meeting_notes_2017_oct-19.1509213749.txt.gz · Last modified: 2017/10/28 18:02 by rimma_belenkaya
Page Tools
